Sernova Corp. (OTCMKTS:SEOVF - Get Free Report) was the recipient of a large decline in short interest during the month of December. As of December 15th, there was short interest totalling 149,000 shares, a decline of 33.2% from the November 30th total of 222,900 shares. Based on an average daily volume of 68,200 shares, the days-to-cover ratio is currently 2.2 days.
Sernova Stock Down 6.4 %
Shares of OTCMKTS:SEOVF traded down $0.01 during midday trading on Friday, hitting $0.15. The stock had a trading volume of 200,506 shares, compared to its average volume of 28,430. The company has a market cap of $50.26 million, a P/E ratio of -1.93 and a beta of 1.14. Sernova has a 12 month low of $0.14 and a 12 month high of $0.55. The business's 50-day simple moving average is $0.17 and its 200-day simple moving average is $0.19.
Sernova (OTCMKTS:SEOVF - Get Free Report) last announced its quarterly earnings data on Monday, December 23rd. The company reported ($0.01) EPS for the quarter.
About Sernova
(
Get Free Report)
Sernova Corp. operates as a clinical-stage regenerative medicine therapeutics company in Canada. The company focuses on the development and commercialization of regenerative medicine therapeutics, including its proprietary Cell Pouch and associated technologies consisting of therapeutic cells and local cellular immune protection.
Further Reading
Before you consider Sernova, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Sernova wasn't on the list.
While Sernova currently has a "Hold" rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Click the link below and we'll send you MarketBeat's list of seven best retirement stocks and why they should be in your portfolio.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.